04/11/2024
5:30 AM | Akari Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/01/2024
5:30 AM | Akari Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/29/2024
3:15 PM | Akari Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/11/2024
4:25 PM | Akari Therapeutics (Subject)
| Form 425 | |
03/11/2024
4:24 PM | Akari Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/05/2024
7:28 AM | Akari Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/05/2024
7:34 AM | Akari Therapeutics (Subject)
| Form 425 | |
|
01/09/2024
4:25 PM | Akari Therapeutics (Filer)
| Form D
Notice of Exempt Offering of Securities | |
01/04/2024
11:34 AM | Akari Therapeutics (Subject)
RPC Pharma Ltd (Filed by)
| Form SC 13D/A | |
01/02/2024
7:00 PM | Akari Therapeutics (Issuer)
DICICCO WENDY F (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
01/02/2024
7:06 PM | Akari Therapeutics (Issuer)
Jacques Rachelle Suzanne (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
01/02/2024
6:56 PM | Akari Therapeutics (Issuer)
Patel Samir Rashmikant (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
01/02/2024
6:49 PM | Akari Therapeutics (Issuer)
Hashad Mohamed Wa'el Ahmed (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
01/02/2024
5:58 PM | Akari Therapeutics (Issuer)
Prudo-Chlebosz Raymond (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
01/02/2024
5:35 PM | Akari Therapeutics (Issuer)
WILLIAMS DONALD A (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
01/02/2024
5:41 PM | Akari Therapeutics (Issuer)
Grissinger Michael (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
12/01/2023
7:00 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/16/2023
7:00 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/27/2023
3:15 PM | Akari Therapeutics (Filer)
| Form 424B3 | |
10/26/2023
11:15 PM | Akari Therapeutics (Filer)
| Form EFFECT | |
10/23/2023
11:15 PM | Akari Therapeutics (Filer)
| Form EFFECT | |
10/23/2023
11:15 PM | Akari Therapeutics (Filer)
| Form EFFECT | |
10/20/2023
4:00 PM | Akari Therapeutics (Subject)
RPC Pharma Ltd (Filed by)
| Form SC 13D/A | |
10/20/2023
3:28 PM | Akari Therapeutics (Filer)
| Form POS AM | |
10/20/2023
3:29 PM | Akari Therapeutics (Filer)
| Form POS AM | |
10/20/2023
3:23 PM | Akari Therapeutics (Filer)
| Form F-3
Registration statement for securities of certain foreign private issuers | |
10/19/2023
3:17 PM | Akari Therapeutics (Filer)
| Form D
Notice of Exempt Offering of Securities | |
10/12/2023
3:43 PM | Akari Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
09/29/2023
7:01 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/21/2023
7:00 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/05/2023
8:00 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/18/2023
7:00 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/17/2023
3:27 PM | Akari Therapeutics (Subject)
Deutsche Bank Trust Co Americas/ ADR Group (Filed by)
| Form F-6 POS | |
08/15/2023
7:00 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/02/2023
7:00 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/27/2023
7:00 AM | Akari Therapeutics (Filer)
Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/25/2023
7:30 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/19/2023
7:00 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/13/2023
7:30 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/11/2023
7:30 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/06/2023
7:30 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Global crypto currency reset (41 major banks signed up) (Ad) Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. |
07/05/2023
7:30 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/30/2023
3:30 PM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/06/2023
11:15 PM | Akari Therapeutics (Filer)
| Form EFFECT | |
06/06/2023
11:15 PM | Akari Therapeutics (Filer)
| Form EFFECT | |
06/06/2023
7:59 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/31/2023
3:39 PM | Akari Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
05/22/2023
7:30 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/05/2023
7:00 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/01/2023
7:05 AM | Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/25/2023
3:20 PM | Akari Therapeutics (Filer)
Akari Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
